Technical Analysis for GRTS - Gritstone Oncology, Inc.
|Grade||Last Price||% Change||Price Change|
GRTS closed down 7.08 percent on Monday, December 17, 2018, on 1.13 times normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical GRTS trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 17||New Downtrend||Bearish||0.00%|
|Dec 17||50 DMA Support||Bullish||0.00%|
|Dec 17||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.00%|
|Dec 17||Multiple of Ten Bullish||Other||0.00%|
|Dec 17||Strong but Oversold||Other||0.00%|
|Dec 17||Wide Bands||Range Expansion||0.00%|
|Dec 17||Down 3 Days in a Row||Weakness||0.00%|
|Dec 17||Down 4 Days in a Row||Weakness||0.00%|
|Dec 17||Down 5 Days in a Row||Weakness||0.00%|
|Dec 17||Oversold Stochastic||Weakness||0.00%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
- Earnings date: ???
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more GRTS news...
|52 Week High||32.9|
|52 Week Low||11.22|
|200-Day Moving Average||0.0|
|50-Day Moving Average||20.1394|
|20-Day Moving Average||25.038|
|10-Day Moving Average||26.271|
|Average True Range||2.5824|
|Chandelier Exit (Long, 3 ATRs )||25.1528|
|Chandelier Exit (Short, 3 ATRs )||27.2072|
|Upper Bollinger Band||30.9043|
|Lower Bollinger Band||19.1717|
|Percent B (%b)||0.12|
|MACD Signal Line||1.9742|
|Market Cap||262.88 Thousand|
|Num Shares||12.8 Thousand|
|Price-to-Earnings (P/E) Ratio||0.00|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||26.58|
|Resistance 3 (R3)||27.01||25.46||25.59|
|Resistance 2 (R2)||25.46||23.94||25.24||25.25|
|Resistance 1 (R1)||23.03||23.00||22.26||22.60||24.92|
|Support 1 (S1)||19.05||19.96||18.28||18.62||16.30|
|Support 2 (S2)||17.50||19.02||17.28||15.97|
|Support 3 (S3)||15.07||17.50||15.64|
|Support 4 (S4)||14.64|